Skip to main content

Table 2 Demographic characteristics

From: Therapy of chronic hepatitis C in people who inject drugs: focus on adherence

  PWID group (N = 101) Control group (N = 177) p
Male sex 66 (65.3%) 91 (51.4%) 0.02
Age (years, median, range) 40 (22–68) 59 (22–87) < 0.001
Foreigners 12 (11.9%) 37 (20.9%) N. S.
Mode of transmission
 Intravenous drug use 101 (100%)   < 0.001
 Blood transfusion   49 (27.7%)  
 Tattoo   11 (62%)  
 Sexual transmission   2 (1.1%)  
 Nosocomial acquisition   16 (9.0%)  
 Professional exposure   13 (7.4%)  
 Men having sex with men   4 (2.3%)  
 Unknown   82 (46.3%)  
Abstinence
 Recent or ongoing drug use 19 (18.8%) N. A  
 > 1 year 24 (23.8%)   
 > 5 years 58 (57.4%)   
Opioid substitution therapy
 Methadone 2 (2%) N. A  
 Buprenorphine 0 (0%)   
HCV genotype
 1a 34 (33.7%) 13 (7.3%) < 0.001
 1b 45 (44.5%) 148 (83.7%)  
 3 19 (18.8%) 13 (7.3%)  
 Other 3 (3%) 3 (1.7%)  
Baseline HCV RNA (IU/mL, median, range) 763,000 (35–13,500,000) 1,340,000 (912–24,900,000) 0.04
Fibrosis stage (Metavir score)
 F0–F1 41 (40.6%) 72 (40.7%)  
 F2 27 (26.7%) 29 (16.4%) 0.02
 F3 13 (12.9%) 14 (7.9%)  
 F4 20 (19.8%) 62 (35.0%)  
  1. P value of < 0.05 was considered statistically significant and the results are displayed in bold
  2. PWID people who inject drugs group